Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics.
| Title: | Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics. |
|---|---|
| Authors: | Mavingire N; Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA.; Moore JC; Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA.; Johnson JR; Department of Microbiology, Biochemistry, & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA.; Dwead AM; Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA.; Cropp CD; Department of Pharmacology & Toxicology, Morehouse School of Medicine, Atlanta, GA 30310, USA.; Mechref Y; Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.; Kobeissy F; Department of Neurobiology, Morehouse School of Medicine, Atlanta, GA 30310, USA.; Rais-Bahrami S; Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35294, USA.; Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35294, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35294, USA.; Woods-Burnham L; Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA. |
| Source: | Cancers [Cancers (Basel)] 2024 Sep 25; Vol. 16 (19). Date of Electronic Publication: 2024 Sep 25. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI |
| Abstract: | Human epidermal growth factor receptor 2 (HER2) is a major driver of disease progression, treatment resistance, and worse survival for patients with various types of cancers, including prostate cancer. However, key bench studies and clinical trials have failed to evaluate the role of HER2 in prostate cancer using racially diverse experimental designs and protocols. This lack of diversity represents what has been the status quo of cancer research in the United States for decades. In the case of prostate cancer, homogenic study designs are problematic as Black men are much more likely to be diagnosed and die from aggressive and incurable forms of the disease. Therefore, the strategic inclusion of biospecimens collected from Black patients as well as the recruitment and enrollment of Black men into prostate cancer clinical trials is necessary to comprehensively evaluate genetic and molecular factors that contribute to variable outcomes in this high-risk population. Additionally, a higher prevalence of HER2 expression in Black men was recently reported in a small cohort of prostate cancer patients and may contribute to worsened prognosis. In this review, we carefully consider the role of HER2 in prostate cancer while, for the first time, taking into account the influences of race and genetic ancestry. |
| References: | Clin Cancer Res. 2010 Mar 1;16(5):1553-60. (PMID: 20179235); Cells. 2019 Jan 20;8(1):. (PMID: 30669516); Cancer Sci. 2021 Jul;112(7):2781-2791. (PMID: 33960594); Ann Diagn Pathol. 2023 Dec;67:152219. (PMID: 38622987); Ann Oncol. 2008 Feb;19(2):269-75. (PMID: 17998285); Cancer. 1997 Jun 1;79(11):2162-70. (PMID: 9179063); Ther Adv Urol. 2022 Jun 14;14:17562872221103988. (PMID: 35719272); J Clin Oncol. 2019 Feb 10;37(5):403-410. (PMID: 30576268); Prostate. 2016 Aug;76(11):994-1003. (PMID: 27098584); Prostate Cancer Prostatic Dis. 2022 Sep;25(3):513-523. (PMID: 34645983); J Clin Oncol. 2022 Aug 10;40(23):2612-2635. (PMID: 35640077); BMC Cancer. 2019 Jan 8;19(1):38. (PMID: 30621632); Am J Pathol. 2002 Jan;160(1):339-45. (PMID: 11786427); Cancer Res. 2008 Feb 1;68(3):927-36. (PMID: 18245496); CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751); Cancer Med. 2023 Jul;12(13):14375-14386. (PMID: 37081739); N Engl J Med. 2016 Sep 22;375(12):1109-12. (PMID: 27653561); Cent European J Urol. 2020;73(3):300-306. (PMID: 33133657); Science. 1987 Jan 9;235(4785):177-82. (PMID: 3798106); Mol Cancer Res. 2008 Mar;6(3):446-57. (PMID: 18337451); Pharmacol Ther. 2021 Dec;228:107932. (PMID: 34174272); William Mary Q. 2001;58(1):17-46. (PMID: 18630381); Front Oncol. 2022 Dec 22;12:989761. (PMID: 36620598); Int J Cancer. 2008 Dec 1;123(11):2636-43. (PMID: 18767043); J Urol. 2002 Oct;168(4 Pt 1):1412-4. (PMID: 12352406); Cancer Med. 2023 Jul;12(13):14623-14635. (PMID: 37184135); Cancer Lett. 1996 Feb 6;99(2):185-9. (PMID: 8616823); Int J Cancer. 1999 Aug 20;84(4):421-5. (PMID: 10404097); Nat Rev Urol. 2022 Mar;19(3):133-134. (PMID: 34815564); Adv Healthc Mater. 2023 Jun;12(14):e2201434. (PMID: 36461624); Prostate Cancer Prostatic Dis. 2023 Sep;26(3):441-442. (PMID: 37117304); Nature. 2021 Dec;600(7890):727-730. (PMID: 34912120); Oncol Lett. 2016 Dec;12(6):4651-4658. (PMID: 28105172); Prostate. 2009 Nov 1;69(15):1660-7. (PMID: 19644954); Am J Kidney Dis. 1993 Apr;21(4 Suppl 1):10-4. (PMID: 8465830); Endocr Relat Cancer. 2019 Apr 01;26(4):R195-R209. (PMID: 31294537); J Urol. 1993 Nov;150(5 Pt 1):1427-33. (PMID: 8105108); Nat Rev Urol. 2024 Jul;21(7):422-432. (PMID: 38307952); Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16392-7. (PMID: 21930937); J Clin Oncol. 2013 May 10;31(14):1726-31. (PMID: 23569315); J Urol. 2001 Oct;166(4):1514-9. (PMID: 11547123); Cancer Biol Ther. 2020 May 3;21(5):463-475. (PMID: 32089070); Cancer Cell. 2004 Nov;6(5):459-69. (PMID: 15542430); Am J Clin Pathol. 2001 Aug;116(2):234-9. (PMID: 11488070); Cancer Res. 2004 Mar 15;64(6):2270-305. (PMID: 15026373); Cancer. 2002 Feb 15;94(4):980-6. (PMID: 11920466); Clin Cancer Res. 2023 Jul 5;29(13):2351-2361. (PMID: 36574481); Infect Agent Cancer. 2009 Feb 10;4 Suppl 1:S3. (PMID: 19208208); J Womens Health (Larchmt). 2011 Oct;20(10):1543-50. (PMID: 21721934); Breast Cancer Res. 2023 May 25;25(1):58. (PMID: 37231433); Cancers (Basel). 2021 Nov 29;13(23):. (PMID: 34885125); Clin Cancer Res. 2020 Sep 15;26(18):4933-4946. (PMID: 32576626); Oncogene. 2013 Dec 5;32(49):5501-11. (PMID: 23752182); Nat Genet. 2014 Oct;46(10):1103-9. (PMID: 25217961); Cancers (Basel). 2023 Jan 11;15(2):. (PMID: 36672410); Cell Oncol. 2010;32(5-6):361-72. (PMID: 20413845); Sci Rep. 2021 Mar 4;11(1):5118. (PMID: 33664329); Biomolecules. 2021 May 12;11(5):. (PMID: 34066020); Ther Adv Med Oncol. 2020 Jun 27;12:1758835920936090. (PMID: 32647540); Nat Protoc. 2013 May;8(5):836-48. (PMID: 23558784); CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766); Cancers (Basel). 2014 Apr 09;6(2):829-59. (PMID: 24722453); Oncogene. 1990 Jul;5(7):953-62. (PMID: 1973830); Urology. 2006 Jul;68(1):110-5. (PMID: 16806433); Eur Urol. 2016 Apr;69(4):557-560. (PMID: 26563871); Front Oncol. 2022 Aug 10;12:928357. (PMID: 36033462); J Urol. 2005 Feb;173(2):342-59. (PMID: 15643172); Mol Biol Int. 2014;2014:852748. (PMID: 25276427); Clin Exp Metastasis. 1999;17(7):545-54. (PMID: 10845553); Mod Pathol. 2014 Jan;27(1):4-18. (PMID: 23807776); CA Cancer J Clin. 2019 May;69(3):211-233. (PMID: 30762872); Arch Pathol Lab Med. 2011 Jan;135(1):55-62. (PMID: 21204711); Hum Pathol. 1997 Jul;28(7):827-33. (PMID: 9224752); Mol Cell Proteomics. 2016 Aug;15(8):2641-70. (PMID: 27250205); Prostate. 2001 Nov 1;49(3):166-71. (PMID: 11746261); Am J Phys Anthropol. 2021 Jun;175(2):363-375. (PMID: 32935870); Free Radic Biol Med. 2012 Jul 1;53(1):95-108. (PMID: 22561705); J Steroid Biochem Mol Biol. 2015 May;149:118-27. (PMID: 25683269); Cancer Res. 1999 Feb 15;59(4):803-6. (PMID: 10029066); Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1771-1783. (PMID: 31455670); Int J Mol Sci. 2020 Jun 25;21(12):. (PMID: 32630372); J Clin Oncol. 2007 Jan 1;25(1):118-45. (PMID: 17159189); Bioinformatics. 2003 Nov 1;19(16):2155-7. (PMID: 14594725); Genome Biol. 2009;10(12):R141. (PMID: 20025784); Eur Urol. 2006 Feb;49(2):245-57. (PMID: 16413664); J Cell Physiol. 2000 Feb;182(2):150-62. (PMID: 10623878); Lancet. 2012 Feb 18;379(9816):633-40. (PMID: 22257673); Prostate. 2004 Sep 1;60(4):332-7. (PMID: 15264245); Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):3-10. (PMID: 29054978); Cancer Res Treat. 2012 Mar;44(1):50-6. (PMID: 22500161); Cancer J. 2001 Sep-Oct;7(5):395-403. (PMID: 11693898); Lancet. 2024 Apr 27;403(10437):1683-1722. (PMID: 38583453); Breast Cancer Res. 2024 May 31;26(1):88. (PMID: 38822357); Exp Biol Med (Maywood). 2018 Feb;243(3):213-221. (PMID: 29405771); Ther Adv Urol. 2013 Dec;5(6):318-29. (PMID: 24294290); Cancer. 2004 May 15;100(10):2125-31. (PMID: 15139054); Urol Oncol. 2013 Feb;31(2):211-8. (PMID: 21784672); Nat Commun. 2021 Feb 18;12(1):1117. (PMID: 33602919); J Gastrointest Surg. 2012 Oct;16(10):1821-9. (PMID: 22843084); Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):891-7. (PMID: 23515145); Front Oncol. 2023 Apr 24;13:1159557. (PMID: 37168382); Cancer Med. 2019 Nov;8(16):6915-6922. (PMID: 31568648); J Cell Biochem. 1999 Jul 1;74(1):23-30. (PMID: 10381258); Endocr Relat Cancer. 2022 Aug 17;29(10):R143-R155. (PMID: 35900853); J Natl Cancer Inst. 2014 Apr 28;106(5):. (PMID: 24777111); Nat Rev Genet. 2004 Aug;5(8):611-8. (PMID: 15266343); Prostate. 2008 May 1;68(6):629-39. (PMID: 18213636); Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1003-1009. (PMID: 30787054); J Transl Med. 2022 May 10;20(1):206. (PMID: 35538576); Nat Rev Drug Discov. 2023 Feb;22(2):101-126. (PMID: 36344672); Hum Genet. 2001 Sep;109(3):253-61. (PMID: 11702204); Front Immunol. 2016 Feb 22;7:53. (PMID: 26941739); Surg Oncol. 1992 Apr;1(2):151-5. (PMID: 1285216) |
| Grant Information: | D-0005 Robert A. Welch Foundation; U01 CA225753 United States CA NCI NIH HHS; 20YOUN04 Prostate Cancer Foundation; R01 GM112490 United States GM NIGMS NIH HHS; TL1TR002382 United States GF NIH HHS; UL1 TR002378 United States GF NIH HHS; R25GM058268 NIH/NIGMS; 2U54MD007602 NIH/NIMHD; 1R01GM112490 United States GF NIH HHS; Accelerate Precision Health Chan Zuckerberg Initiative; R01 GM130091 United States GM NIGMS NIH HHS; KL2TR002381 United States GF NIH HHS; U54CA118638 NIH/NCI; W81XWH2110038 Department of Defense Prostate Cancer Research Program; 1R01GM130091 United States GF NIH HHS; 1U01CA225753 United States GF NIH HHS |
| Contributed Indexing: | Keywords: Black men; ERBB2; HER2; genetic ancestry; omics; prostate cancer |
| Entry Date(s): | Date Created: 20241016 Latest Revision: 20260307 |
| Update Code: | 20260307 |
| PubMed Central ID: | PMC11476348 |
| DOI: | 10.3390/cancers16193262 |
| PMID: | 39409883 |
| Database: | MEDLINE |
Journal Article; Review